ijms-logo

Journal Browser

Journal Browser

Autoimmune and Inflammatory Diseases: Latest Advances and Prospects

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (30 January 2026) | Viewed by 698

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory Medicine, Department of Medicine DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
Interests: autoimmunity; autoimmune disease; inflammatory disease; autoinflammatory diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am pleased to invite you to contribute to this Special Issue of IJMS, entitled “Autoimmune and Inflammatory Diseases: Latest Advances and Prospects”.

Inflammatory diseases encompass a wide range of disorders and conditions characterized by inflammation, from asthma to coeliac disease, and from autoimmune diseases to inflammatory bowel disease. Extensive research into the pathophysiology of these diseases has shown that various factors are involved in their pathogenesis. Since autoimmune and inflammatory diseases remain a major medical problem, the molecular mechanisms of which are still not fully understood, new knowledge is needed in this field.

Emerging data suggest that environmental triggers may act through peculiar cellular pathways. A comprehensive and deep understanding of these mechanisms will enable tailored therapy. Given the heterogeneity of autoimmune and inflammatory mechanisms, insights in this area are likely to lead to personalized molecular medicine. Cellular mechanisms coupled with various mechanisms at the molecular level have been proposed as a possible explanation for the loss of self-tolerance, whereby immune cells can no longer distinguish between “self” and “non-self” antigens.

Novel studies ranging from basic and translational research at the molecular level to pathogenetic mechanisms and clinical applications are expected to contribute to new insights in this field. The submission of such studies to this Special Issue is very welcome.

Dr. Paola Galozzi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmunity
  • autoimmune disease
  • inflammation
  • inflammatory disease
  • cellular pathways
  • molecular mechanisms
  • pathogenesis
  • therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2507 KB  
Article
Recombinant Human IgG1-Hexamer Reduces Pathogenic Autoantibodies in the K/BxN Mouse Model of Arthritis Independent of FcRn
by Bonnie J. B. Lewis, Ruqayyah J. Almizraq, Selena Cen, Beth Binnington, Kayluz Frias Boligan, Rolf Spirig, Fabian Käsermann, Shannon E. Dunn and Donald R. Branch
Int. J. Mol. Sci. 2026, 27(3), 1277; https://doi.org/10.3390/ijms27031277 - 27 Jan 2026
Viewed by 117
Abstract
Arthritis in K/BxN mice is provoked by pathogenic autoantibodies to glucose-6-phosphate isomerase (G6PI), which is a ubiquitously expressed enzyme that is present in cells, in the circulation and on the articular cartilage. When G6PI autoantibodies (auto-Abs) deposit on the articular cartilage of K/BxN [...] Read more.
Arthritis in K/BxN mice is provoked by pathogenic autoantibodies to glucose-6-phosphate isomerase (G6PI), which is a ubiquitously expressed enzyme that is present in cells, in the circulation and on the articular cartilage. When G6PI autoantibodies (auto-Abs) deposit on the articular cartilage of K/BxN mice, arthritis ensues due to the activation of various components of the innate immune system. Recent studies have investigated the in vivo efficacy of recombinant fragment-crystallizable (Fc) protein-based therapeutics. Many of the recombinant Fc proteins that have been evaluated have been shown to have a protective effect in mouse models of arthritis, such as the K/BxN serum-transfer model. More recently, rFc-µTP-L309C, a recombinant human IgG1-Fc with an additional point mutation at position L309C fused to the human IgM tailpiece to form a hexamer, has been shown to ameliorate the arthritis in K/BxN mice. Additional studies have shown that rFc-µTP-L309C has multiple effects that work together to ameliorate the arthritis, including inhibition of neutrophil migration into the joint, inhibition of IL-1β production, downregulation of Th1 and Th17 cells and increases in T regulatory cells and synovial fluid IL-10. In this work, rFc-µTP-L309C was shown to effectively prevent arthritis in the K/BxN serum-transfer model, significantly downregulate inflammatory cytokines/chemokines and ameliorate the arthritis in the endogenous K/BxN model. This amelioration of the arthritis was mediated by a significant decrease in antibody levels. Interestingly, this effect seems to be independent of the neonatal Fc receptor (FcRn). rFc-µTP-L309C was shown to specifically inhibit G6PI autoantibody secretion from B-cells with a concomitant increase in TGFβ and decrease in B-cell activating factor (BAFF). These new findings suggest that rFc-µTP-L309C may provide a therapeutic benefit for other antibody-mediated autoimmune disease through its effects on B-cells. Full article
(This article belongs to the Special Issue Autoimmune and Inflammatory Diseases: Latest Advances and Prospects)
Back to TopTop